Drug profile · INN
daclatasvir dihydrochloride
DAKLINZA
daclatasvir dihydrochloride (DAKLINZA) is a nonstructural protein 5a inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — daclatasvir dihydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
daclatasvir dihydrochloride (DAKLINZA) is a nonstructural protein 5a inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Nonstructural protein 5A inhibitor
Primary target: Nonstructural protein 5A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is daclatasvir dihydrochloride?
daclatasvir dihydrochloride (DAKLINZA) is a nonstructural protein 5a inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for daclatasvir dihydrochloride?
DAKLINZA is a marketed brand name for daclatasvir dihydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of daclatasvir dihydrochloride?
daclatasvir dihydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.